On Monday, AstraZeneca plc AZN entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia..

周一，阿斯利康股份有限公司AZN与香港CSPC制药集团有限公司签订了独家许可协议，以推进早期新型小分子脂蛋白（a）（Lp（a））干扰物的开发，该干扰物有可能为血脂异常患者提供额外的益处。。

Dyslipidemia is a metabolic disorder that occurs when there are abnormal levels of lipids or fats, such as cholesterol and triglycerides, in the blood.

血脂异常是一种代谢紊乱，当血液中的脂质或脂肪（如胆固醇和甘油三酯）水平异常时就会发生。

Under the terms of the agreement, AstraZeneca will receive access to CSPC's pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, to develop the lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibitor, AZD0780..

。。

Also Read: AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review.

另请阅读：阿斯利康寻求扩大血癌药物Calquence的使用，FDA授予优先审查。

YS2302018 was discovered by CSPC and has been shown to prevent the formation of Lp(a).

YS2302018是由CSPC发现的，已被证明可以防止Lp（a）的形成。

Lp(a) is a form of low-density lipoprotein (LDL) that plays a key role in cholesterol transport in the bloodstream.

Lp（a）是低密度脂蛋白（LDL）的一种形式，在血液中胆固醇的运输中起着关键作用。

Elevated levels of Lp(a) and elevated LDL cholesterol are known risk factors for cardiovascular disease.

Lp（a）水平升高和LDL胆固醇升高是心血管疾病的已知危险因素。

CSPC will receive an upfront payment of $100 million from AstraZeneca and is eligible to receive up to $1.92 billion for further development and commercialization milestones, plus tiered royalties.

。

On Monday, AstraZeneca released topline data from BATURA Phase 3b trial of inhaled Airsupra (albuterol/budesonide) as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.

周一，阿斯利康（AstraZeneca）发布了巴图拉（BATURA）3b期吸入性艾司普拉（沙丁胺醇/布地奈德）试验的topline数据，作为对症状的必要救援药物，与沙丁胺醇相比。

The study met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of severe exacerbation.

该研究达到了主要终点，证明了严重恶化风险的统计学显着和临床意义的降低。

The trial included patients with intermittent or mild persistent asthma.

该试验包括间歇性或轻度持续性哮喘患者。

Asthma affects as many as 262 million people worldwide, including over 25 million in the U.S.

哮喘影响全球多达2.62亿人，其中美国超过2500万人。

Patients with mild asthma comprise at least 50% of the U.S. asthma population and are at risk of severe exacerbations.

轻度哮喘患者至少占美国哮喘人群的50%，并且有严重恶化的风险。

Airsupra is the first and only anti-inflammatory rescue medication approved in the U.S. for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

Airsupra是美国批准的第一种也是唯一一种抗炎救援药物，用于根据需要治疗或预防支气管收缩，并降低18岁及以上哮喘患者恶化的风险。

The US approval was based on MANDALA and DENALI Phase 3 trial results.

美国的批准是基于MANDALA和DENALI的3期试验结果。

Airsupra is also being studied in adolescents with asthma in the ACADIA Phase 3 trial and in patients in China in the BAIYUN Phase 3 trial.

Airsupra也正在ACADIA 3期试验中对哮喘青少年进行研究，并在白云3期试验中对中国患者进行研究。

Price Action: AZN stock is down 0.68% at $76.94 during the premarket session at last check Monday.

价格走势：AZN股价在周一最后一次检查的上市前交易中下跌0.68%，至76.94美元。

Read Next:

阅读下一页：

Warner Music Hit By Streaming Volatility And Execution Risks: Analyst.

分析师表示，华纳音乐受到流媒体波动性和执行风险的冲击。

Image by Robert Way via ShutterstockMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Robert Way通过ShutterstockMarket News拍摄的图片以及Benzinga API提供给您的数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。